Effect of Intranasal Midazolam Versus Ketamine Midazolam Combination as a Premedication on the Oc… (NCT06122948) | Clinical Trial Compass
CompletedPhase 3
Effect of Intranasal Midazolam Versus Ketamine Midazolam Combination as a Premedication on the Occurrence of Postoperative Respiratory Adverse Events
Egypt200 participantsStarted 2023-11-04
Plain-language summary
The aim of this study is to investigate the effect of addition of intranasal ketamine to midazolam compared to midazolam alone as a premedication on the occurrence of PRAEs
Who can participate
Age range3 Years – 12 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children both sexes male and female.
* Age from 3 to 12 years old.
* ASA grade I, II.
* undergoing elective AT procedures.
Exclusion Criteria:
* Congenital heart diseases (cyanotic and a cyanotic).
* Congenital syndromes affecting airway anatomy such as Pierre-Robin syndrome and Down syndrome.
* Severe lung diseases affecting either lung tissue such as pulmonary cystic fibrosis and idiopathic pulmonary fibrosis or affecting lung circulation such as pulmonary hypertension with marked limitation of Physical activity or inability to carry out any physical activity according to NHYA classification.
* Recent upper respiratory tract infection (less than two weeks).
* Neuromuscular diseases including cerebral palsy and epilepsy.
What they're measuring
1
The incidence of any perioperative respiratory adverse events (PRAEs)